Table 1 Clinical characteristics of the COVID-19 patients passed quality controls in this study.
From: Genome-wide association study of COVID-19 severity among the Chinese population
Categories | Huoshenshan cohort | P values | Union cohort | P values | ||
|---|---|---|---|---|---|---|
Cases (n = 663) | Controls (n = 322) | Cases (n = 200) | Controls (n = 207) | |||
Age, years | ||||||
Mean (SD) | 64.2 (13.7) | 56.6 (13.9) | 1.4 × 10−15 | 61.8 (14.0) | 52.2 (16.2) | 5.0 × 10−10 |
< 65, n (%) | 305 (46.0) | 214 (66.5) | 2.5 × 10−9 | 106 (53.0) | 160 (77.3) | 4.5 × 10−7 |
≥ 65, n (%) | 358 (54.0) | 108 (33.5) | – | 94 (47.0) | 47 (22.7) | – |
Gender, n (%) | 0.88 | 0.082 | ||||
Male | 343 (51.7) | 169 (52.5) | – | 111 (55.5) | 96 (46.4) | – |
Female | 320 (48.3) | 153 (47.5) | – | 89 (44.5) | 111 (53.7) | – |
Comorbidities, n (%) | ||||||
Hypertension | 251 (37.9) | 90 (28.0) | 0.0027 | 77 (38.5) | 62 (30.0) | 0.042 |
Diabetes | 119 (17.9) | 37 (11.5) | 0.012 | 37 (18.5) | 26 (12.6) | 0.13 |
Coronary artery diseases | 61 (9.2) | 14 (4.3) | 0.010 | 28 (14.0) | 9 (4.3) | 0.0013 |
Chronic hepatitis B | 16 (2.4) | 9 (2.8) | 0.89 | 3 (1.5) | 1 (0.5) | 0.36 |
Chronic obstructive pulmonary disease | 14 (2.1) | 1 (0.0) | 0.028 | 6 (3.0) | 0 (0.0) | 0.014 |
Chronic renal diseases | 6 (0.1) | 2 (0.1) | 1.00 | 3 (1.5) | 0 (0.0) | 0.12 |
Cancers | 24 (3.6) | 5 (1.6) | 0.11 | 13 (6.5) | 5 (2.4) | 0.054 |
Symptoms, n (%) | ||||||
Fever | 470 (70.9) | 205 (63.7) | 0.027 | 143 (71.5) | 132 (63.8) | 0.12 |
Cough | 506 (76.3) | 209 (64.9) | 0.00022 | 142 (71.0) | 123 (59.4) | 0.014 |
Headache | 15 (2.3) | 3 (0.1) | 0.20 | 13 (6.5) | 6 (2.9) | 0.14 |
Fatigue | 343 (51.7) | 152 (47.2) | 0.21 | 96 (48.0) | 68 (32.9) | 0.0026 |
Pharyngalgia | 15 (2.3) | 7 (2.2) | 1.00 | 7 (3.5) | 7 (3.4) | 1.00 |
Dyspnea | 51 (7.7) | 7 (2.2) | 9.4 × 10−4 | 25 (12.5) | 4 (1.9) | 2.6 × 10−5 |
Death, n (%) | 30 (4.5) | 0 (0.0) | 9.9 × 10−6 | 21 (10.5) | 0 (0.0) | 1.9 × 10−7 |
